Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 69 entries
Sorted by: Best Match Show Resources per page
Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.

ChemistryOpen

Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T.
PMID: 24808990
ChemistryOpen. 2014 Apr;3(2):48-53. doi: 10.1002/open.201402000. Epub 2014 Apr 06.

The need for post-synthetic modifications and reactive prosthetic groups has long been a limiting factor in the synthesis and study of peptidic and peptidomimetic imaging agents. In this regard, the application of biologically and chemically orthogonal reactions to the...

Cite
Zeglis BM, Emmetiere F, Pillarsetty N, et al. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen. 2014;3(2):48-53doi: 10.1002/open.201402000.
Zeglis, B. M., Emmetiere, F., Pillarsetty, N., Weissleder, R., Lewis, J. S., & Reiner, T. (2014). Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen, 3(2), 48-53. https://doi.org/10.1002/open.201402000
Zeglis, Brian M, et al. "Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis." ChemistryOpen vol. 3,2 (2014): 48-53. doi: https://doi.org/10.1002/open.201402000
Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T. Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. ChemistryOpen. 2014 Apr;3(2):48-53. doi: 10.1002/open.201402000. Epub 2014 Apr 06. PMID: 24808990; PMCID: PMC4000166.
Copy Download .nbib Format: NLM
Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Chemical communications (Cambridge, England)

Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, Smith G.
PMID: 28703825
Chem Commun (Camb). 2017 Jul 27;53(61):8529-8532. doi: 10.1039/c7cc03572a.

The future of

Cite
Allott L, Da Pieve C, Meyers J, et al. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chem Commun (Camb). 2017;53(61):8529-8532doi: 10.1039/c7cc03572a.
Allott, L., Da Pieve, C., Meyers, J., Spinks, T., Ciobota, D. M., Kramer-Marek, G., & Smith, G. (2017). Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chemical communications (Cambridge, England), 53(61), 8529-8532. https://doi.org/10.1039/c7cc03572a
Allott, L, et al. "Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89." Chemical communications (Cambridge, England) vol. 53,61 (2017): 8529-8532. doi: https://doi.org/10.1039/c7cc03572a
Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, Smith G. Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chem Commun (Camb). 2017 Jul 27;53(61):8529-8532. doi: 10.1039/c7cc03572a. PMID: 28703825; PMCID: PMC6055981.
Copy Download .nbib Format: NLM
A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant .

Dalton transactions (Cambridge, England : 2003)

Bhatt NB, Pandya DN, Rideout-Danner S, Gage HD, Marini FC, Wadas TJ.
PMID: 30178793
Dalton Trans. 2018 Oct 07;47(37):13214-13221. doi: 10.1039/c8dt01841c. Epub 2018 Sep 04.

Zirconium-89 is currently being used in numerous clinical trials involving monoclonal antibodies and positron emission tomography. This report describes a revised strategy that reduces preparation time while increasing the specific activity of clinically relevant immuno-PET agents. Additionally, it demonstrates...

Cite
Bhatt NB, Pandya DN, Rideout-Danner S, et al. A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant . Dalton Trans. 2018;47(37):13214-13221doi: 10.1039/c8dt01841c.
Bhatt, N. B., Pandya, D. N., Rideout-Danner, S., Gage, H. D., Marini, F. C., & Wadas, T. J. (2018). A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant . Dalton transactions (Cambridge, England : 2003), 47(37), 13214-13221. https://doi.org/10.1039/c8dt01841c
Bhatt, Nikunj B, et al. "A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant ." Dalton transactions (Cambridge, England : 2003) vol. 47,37 (2018): 13214-13221. doi: https://doi.org/10.1039/c8dt01841c
Bhatt NB, Pandya DN, Rideout-Danner S, Gage HD, Marini FC, Wadas TJ. A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant . Dalton Trans. 2018 Oct 07;47(37):13214-13221. doi: 10.1039/c8dt01841c. Epub 2018 Sep 04. PMID: 30178793; PMCID: PMC6192516.
Copy Download .nbib Format: NLM
Radiolabeling of PSMA-617 with .

Nuclear medicine and biology

Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, Akimitsu N, Kumakura Y.
PMID: 34998216
Nucl Med Biol. 2021 Dec 23;106:21-28. doi: 10.1016/j.nucmedbio.2021.12.003. Epub 2021 Dec 23.

INTRODUCTION: Novel diagnostic and therapeutic options are urgently needed for patients with metastatic castration-resistant prostate cancer (CRPC). PSMA-617 is one of the most promising ligands that bind to prostate specific membrane antigen (PSMA), the cell surface biomarker of CRPC....

Cite
Imura R, Ozeki AN, Shida N, et al. Radiolabeling of PSMA-617 with . Nucl Med Biol. 2021;106:21-28doi: 10.1016/j.nucmedbio.2021.12.003.
Imura, R., Ozeki, A. N., Shida, N., Kobayashi, M., Ida, H., Wada, Y., Akimitsu, N., & Kumakura, Y. (2021). Radiolabeling of PSMA-617 with . Nuclear medicine and biology, 10621-28. https://doi.org/10.1016/j.nucmedbio.2021.12.003
Imura, Ryota, et al. "Radiolabeling of PSMA-617 with ." Nuclear medicine and biology vol. 106 (2021): 21-28. doi: https://doi.org/10.1016/j.nucmedbio.2021.12.003
Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, Akimitsu N, Kumakura Y. Radiolabeling of PSMA-617 with . Nucl Med Biol. 2021 Dec 23;106:21-28. doi: 10.1016/j.nucmedbio.2021.12.003. Epub 2021 Dec 23. PMID: 34998216.
Copy Download .nbib Format: NLM
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with .

American journal of translational research

Li M, Ehlerding EB, Jiang D, Barnhart TE, Chen W, Cao T, Engle JW, Cai W.
PMID: 32509182
Am J Transl Res. 2020 May 15;12(5):1862-1872. eCollection 2020.

Programmed death protein 1 and programmed death-ligand 1 (PD-1/PD-L1) have been widely studied as one of the most critical immune check-point pairs in the cancer microenvironment. In breast cancer (BrCa), the expression of PD-L1 is regarded as a determinant...

Cite
Li M, Ehlerding EB, Jiang D, et al. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with . Am J Transl Res. 2020;12(5):1862-1872
Li, M., Ehlerding, E. B., Jiang, D., Barnhart, T. E., Chen, W., Cao, T., Engle, J. W., & Cai, W. (2020). In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with . American journal of translational research, 12(5), 1862-1872.
Li, Miao, et al. "In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with ." American journal of translational research vol. 12,5 (2020): 1862-1872.
Li M, Ehlerding EB, Jiang D, Barnhart TE, Chen W, Cao T, Engle JW, Cai W. In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with . Am J Transl Res. 2020 May 15;12(5):1862-1872. eCollection 2020. PMID: 32509182; PMCID: PMC7270013.
Copy Download .nbib Format: NLM
Aerosolized In Vivo 3D Localization of Nose-to-Brain Nanocarrier Delivery Using Multimodality Neuroimaging in a Rat Model-Protocol Development.

Pharmaceutics

Veronesi MC, Graner BD, Cheng SH, Zamora M, Zarrinmayeh H, Chen CT, Das SK, Vannier MW.
PMID: 33804222
Pharmaceutics. 2021 Mar 15;13(3). doi: 10.3390/pharmaceutics13030391.

The fate of intranasal aerosolized radiolabeled polymeric micellar nanoparticles (LPNPs) was tracked with positron emission tomography/computer tomography (PET/CT) imaging in a rat model to measure nose-to-brain delivery. A quantitative temporal and spatial testing protocol for new radio-nanotheranostic agents was...

Cite
Veronesi MC, Graner BD, Cheng SH, et al. Aerosolized In Vivo 3D Localization of Nose-to-Brain Nanocarrier Delivery Using Multimodality Neuroimaging in a Rat Model-Protocol Development. Pharmaceutics. 2021;13(3)doi: 10.3390/pharmaceutics13030391.
Veronesi, M. C., Graner, B. D., Cheng, S. H., Zamora, M., Zarrinmayeh, H., Chen, C. T., Das, S. K., & Vannier, M. W. (2021). Aerosolized In Vivo 3D Localization of Nose-to-Brain Nanocarrier Delivery Using Multimodality Neuroimaging in a Rat Model-Protocol Development. Pharmaceutics, 13(3), . https://doi.org/10.3390/pharmaceutics13030391
Veronesi, Michael C, et al. "Aerosolized In Vivo 3D Localization of Nose-to-Brain Nanocarrier Delivery Using Multimodality Neuroimaging in a Rat Model-Protocol Development." Pharmaceutics vol. 13,3 (2021). doi: https://doi.org/10.3390/pharmaceutics13030391
Veronesi MC, Graner BD, Cheng SH, Zamora M, Zarrinmayeh H, Chen CT, Das SK, Vannier MW. Aerosolized In Vivo 3D Localization of Nose-to-Brain Nanocarrier Delivery Using Multimodality Neuroimaging in a Rat Model-Protocol Development. Pharmaceutics. 2021 Mar 15;13(3). doi: 10.3390/pharmaceutics13030391. PMID: 33804222; PMCID: PMC8001876.
Copy Download .nbib Format: NLM
Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease.

EJNMMI research

Laban KG, Kalmann R, Leguit RJ, de Keizer B.
PMID: 31363937
EJNMMI Res. 2019 Jul 30;9(1):69. doi: 10.1186/s13550-019-0530-9.

No abstract available.

Cite
Laban KG, Kalmann R, Leguit RJ, et al. Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI Res. 2019;9(1):69doi: 10.1186/s13550-019-0530-9.
Laban, K. G., Kalmann, R., Leguit, R. J., & de Keizer, B. (2019). Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI research, 9(1), 69. https://doi.org/10.1186/s13550-019-0530-9
Laban, Kamil G, et al. "Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease." EJNMMI research vol. 9,1 (2019): 69. doi: https://doi.org/10.1186/s13550-019-0530-9
Laban KG, Kalmann R, Leguit RJ, de Keizer B. Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease. EJNMMI Res. 2019 Jul 30;9(1):69. doi: 10.1186/s13550-019-0530-9. PMID: 31363937; PMCID: PMC6667535.
Copy Download .nbib Format: NLM
Synthesis of a novel .

EJNMMI research

Xu Y, Wang L, Pan D, Yan J, Wang X, Yang R, Li M, Liu Y, Yang M.
PMID: 32495181
EJNMMI Res. 2020 Jun 03;10(1):58. doi: 10.1186/s13550-020-00649-7.

BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is an essential biomarker for tumor treatment. Affibody is an ideal vector for preparing HER2 specific probes because of high affinity and rapid clearance from normal tissues, etc. Zirconium-89 is a PET...

Cite
Xu Y, Wang L, Pan D, et al. Synthesis of a novel . EJNMMI Res. 2020;10(1):58doi: 10.1186/s13550-020-00649-7.
Xu, Y., Wang, L., Pan, D., Yan, J., Wang, X., Yang, R., Li, M., Liu, Y., & Yang, M. (2020). Synthesis of a novel . EJNMMI research, 10(1), 58. https://doi.org/10.1186/s13550-020-00649-7
Xu, Yuping, et al. "Synthesis of a novel ." EJNMMI research vol. 10,1 (2020): 58. doi: https://doi.org/10.1186/s13550-020-00649-7
Xu Y, Wang L, Pan D, Yan J, Wang X, Yang R, Li M, Liu Y, Yang M. Synthesis of a novel . EJNMMI Res. 2020 Jun 03;10(1):58. doi: 10.1186/s13550-020-00649-7. PMID: 32495181; PMCID: PMC7271293.
Copy Download .nbib Format: NLM
Radiolabeling of PSMA-617 with .

Nuclear medicine and biology

Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, Akimitsu N, Kumakura Y.
PMID: 34998216
Nucl Med Biol. 2021 Dec 23;106:21-28. doi: 10.1016/j.nucmedbio.2021.12.003. Epub 2021 Dec 23.

INTRODUCTION: Novel diagnostic and therapeutic options are urgently needed for patients with metastatic castration-resistant prostate cancer (CRPC). PSMA-617 is one of the most promising ligands that bind to prostate specific membrane antigen (PSMA), the cell surface biomarker of CRPC....

Cite
Imura R, Ozeki AN, Shida N, et al. Radiolabeling of PSMA-617 with . Nucl Med Biol. 2021;106:21-28doi: 10.1016/j.nucmedbio.2021.12.003.
Imura, R., Ozeki, A. N., Shida, N., Kobayashi, M., Ida, H., Wada, Y., Akimitsu, N., & Kumakura, Y. (2021). Radiolabeling of PSMA-617 with . Nuclear medicine and biology, 10621-28. https://doi.org/10.1016/j.nucmedbio.2021.12.003
Imura, Ryota, et al. "Radiolabeling of PSMA-617 with ." Nuclear medicine and biology vol. 106 (2021): 21-28. doi: https://doi.org/10.1016/j.nucmedbio.2021.12.003
Imura R, Ozeki AN, Shida N, Kobayashi M, Ida H, Wada Y, Akimitsu N, Kumakura Y. Radiolabeling of PSMA-617 with . Nucl Med Biol. 2021 Dec 23;106:21-28. doi: 10.1016/j.nucmedbio.2021.12.003. Epub 2021 Dec 23. PMID: 34998216.
Copy Download .nbib Format: NLM
Light-Activated Protein Conjugation and .

Chemistry (Weinheim an der Bergstrasse, Germany)

Guillou A, Earley DF, Holland JP.
PMID: 32286712
Chemistry. 2020 Jun 05;26(32):7185-7189. doi: 10.1002/chem.202001755. Epub 2020 May 04.

Protein-conjugates are vital tools in biomedical research, drug discovery and imaging science. For example, functionalised monoclonal antibodies (mAbs) coupled to the desferrioxamine B (DFO) chelate and radiolabelled with

Cite
Guillou A, Earley DF, Holland JP. Light-Activated Protein Conjugation and . Chemistry. 2020;26(32):7185-7189doi: 10.1002/chem.202001755.
Guillou, A., Earley, D. F., & Holland, J. P. (2020). Light-Activated Protein Conjugation and . Chemistry (Weinheim an der Bergstrasse, Germany), 26(32), 7185-7189. https://doi.org/10.1002/chem.202001755
Guillou, Amaury, et al. "Light-Activated Protein Conjugation and ." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 26,32 (2020): 7185-7189. doi: https://doi.org/10.1002/chem.202001755
Guillou A, Earley DF, Holland JP. Light-Activated Protein Conjugation and . Chemistry. 2020 Jun 05;26(32):7185-7189. doi: 10.1002/chem.202001755. Epub 2020 May 04. PMID: 32286712.
Copy Download .nbib Format: NLM
A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of .

Dalton transactions (Cambridge, England : 2003)

Buchwalder C, Rodríguez-Rodríguez C, Schaffer P, Karagiozov SK, Saatchi K, Häfeli UO.
PMID: 28713886
Dalton Trans. 2017 Jul 25;46(29):9654-9663. doi: 10.1039/c7dt02196h.

Zirconium-89 (

Cite
Buchwalder C, Rodríguez-Rodríguez C, Schaffer P, et al. A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of . Dalton Trans. 2017;46(29):9654-9663doi: 10.1039/c7dt02196h.
Buchwalder, C., Rodríguez-Rodríguez, C., Schaffer, P., Karagiozov, S. K., Saatchi, K., & Häfeli, U. O. (2017). A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of . Dalton transactions (Cambridge, England : 2003), 46(29), 9654-9663. https://doi.org/10.1039/c7dt02196h
Buchwalder, Christian, et al. "A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of ." Dalton transactions (Cambridge, England : 2003) vol. 46,29 (2017): 9654-9663. doi: https://doi.org/10.1039/c7dt02196h
Buchwalder C, Rodríguez-Rodríguez C, Schaffer P, Karagiozov SK, Saatchi K, Häfeli UO. A new tetrapodal 3-hydroxy-4-pyridinone ligand for complexation of . Dalton Trans. 2017 Jul 25;46(29):9654-9663. doi: 10.1039/c7dt02196h. PMID: 28713886.
Copy Download .nbib Format: NLM
Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development.

Chemical science

Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ.
PMID: 28451334
Chem Sci. 2017 Mar 01;8(3):2309-2314. doi: 10.1039/c6sc04128k. Epub 2016 Dec 13.

We report our initial investigations into the use of tetraazamacrocycles as zirconium-89 chelators. We describe the synthesis and complete characterization of several Zr tetraazamacrocycle complexes, and definitively describe the first crystal structure of zirconium 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Zr-DOTA) using single...

Cite
Pandya DN, Bhatt N, Yuan H, et al. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2016;8(3):2309-2314doi: 10.1039/c6sc04128k.
Pandya, D. N., Bhatt, N., Yuan, H., Day, C. S., Ehrmann, B. M., Wright, M., Bierbach, U., & Wadas, T. J. (2017). Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chemical science, 8(3), 2309-2314. https://doi.org/10.1039/c6sc04128k
Pandya, Darpan N, et al. "Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development." Chemical science vol. 8,3 (2017): 2309-2314. doi: https://doi.org/10.1039/c6sc04128k
Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, Bierbach U, Wadas TJ. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci. 2017 Mar 01;8(3):2309-2314. doi: 10.1039/c6sc04128k. Epub 2016 Dec 13. PMID: 28451334; PMCID: PMC5363373.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 69 entries